193 related articles for article (PubMed ID: 19349790)
1. Anti-VEGF therapy in proliferative diabetic retinopathy.
Abdallah W; Fawzi AA
Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790
[No Abstract] [Full Text] [Related]
2. Anti-VEGF therapeutic approaches for diabetic macular edema.
Khurana RN; Do DV; Nguyen QD
Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
[No Abstract] [Full Text] [Related]
3. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
Jardeleza MS; Miller JW
Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
[TBL] [Abstract][Full Text] [Related]
4. Treatment of diabetic retinopathy with anti-VEGF drugs.
Waisbourd M; Goldstein M; Loewenstein A
Acta Ophthalmol; 2011 May; 89(3):203-7. PubMed ID: 21044274
[TBL] [Abstract][Full Text] [Related]
5. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
Giuliari GP; Guel DA; Cortez MA; Cortez RT
Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
Montero JA; Ruiz-Moreno JM; Correa ME
Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
[TBL] [Abstract][Full Text] [Related]
7. Debate on the various anti-vascular endothelial growth factor drugs.
Khalili MR; Hosseini H
Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
[No Abstract] [Full Text] [Related]
8. Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
Salam A; Mathew R; Sivaprasad S
Acta Ophthalmol; 2011 Aug; 89(5):405-11. PubMed ID: 21294854
[TBL] [Abstract][Full Text] [Related]
9. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of ocular neovascularization: promises and potential problems.
van Wijngaarden P; Coster DJ; Williams KA
JAMA; 2005 Mar; 293(12):1509-13. PubMed ID: 15784876
[No Abstract] [Full Text] [Related]
11. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
Salam A; DaCosta J; Sivaprasad S
Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of neovascular age-related macular degeneration with bevacizumab].
Monzón Moreno A
Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
[No Abstract] [Full Text] [Related]
13. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
14. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
15. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
16. Molecular biology of choroidal neovascularization.
Lu M; Adamis AP
Ophthalmol Clin North Am; 2006 Sep; 19(3):323-34. PubMed ID: 16935207
[TBL] [Abstract][Full Text] [Related]
17. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Nicholson BP; Schachat AP
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
19. Antivascular endothelial growth factor in diabetic retinopathy.
Iacono P; Battaglia Parodi M; Bandello F
Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031
[TBL] [Abstract][Full Text] [Related]
20. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Nagpal M; Nagpal K; Nagpal PN
Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
